Stockreport

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor [Yahoo! Finance]

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF MRT-8102 and other NEK7 program MGDs are potentially applicable across a range of inflammatory disorders, metabolic disorders, as well as ocular and neurological diseas [Read more]